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Abstract
Dysfunction of the central noradrenergic and dopaminergic systems is the primary neurobiological characteristic of
Parkinson’s disease (PD). Importantly, neuronal loss in the locus coeruleus (LC) that occurs in early stages of PD may
accelerate progressive loss of dopaminergic neurons. Therefore, restoring the activity and function of the deficient noradrenergic system may be an important therapeutic strategy for early PD. In the present study, the lentiviral constructions of
transcription factors Phox2a/2b, Hand2 and Gata3, either alone or in combination, were microinjected into the LC region of
the PD model VMAT2 Lo mice at 12 and 18 month age. Biochemical analysis showed that microinjection of lentiviral
expression cassettes into the LC significantly increased mRNA levels of Phox2a, and Phox2b, which were accompanied
by parallel increases of mRNA and proteins of dopamine b-hydroxylase (DBH) and tyrosine hydroxylase (TH) in the LC.
Furthermore, there was considerable enhancement of DBH protein levels in the frontal cortex and hippocampus, as well as
enhanced TH protein levels in the striatum and substantia nigra. Moreover, these manipulations profoundly increased
norepinephrine and dopamine concentrations in the striatum, which was followed by a remarkable improvement of the
spatial memory and locomotor behavior. These results reveal that over-expression of these transcription factors in the LC
improves noradrenergic and dopaminergic activities and functions in this rodent model of PD. It provides the necessary
groundwork for the development of gene therapies of PD, and expands our understanding of the link between the
LC-norepinephrine and dopamine systems during the progression of PD.
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Introduction
The locus coeruleus (LC, A6) is the primary source of
norepinephrine (NE) in the brain, and sends divergent
projections throughout the central nervous system
(Aston-Jones et al., 2000). The hippocampus (HP) and
frontal cortex (FC) are the brain regions to receive sole
noradrenergic innervation from the LC (Haring and
Davis,
1985;
Samuels
and
Szabadi,
2008).
Correspondingly, the substantia nigra pars compacta
(SN, A9) and ventral tegmental area (VTA, A10)
(Anden et al., 1966; Domesick, 1988) are the primary
source of dopamine (DA) in the brain, each of which
sends variant axons throughout the striatum and other
regions of the cerebral cortex. NE and DA play
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important roles in spatial memory, attention, motor
functions, as well as emotional behaviors (Robbins and
Everitt, 1995; Bromberg-Martin et al., 2010). Although
the noradrenergic and dopaminergic systems account for
different functions and activities in the brain, however,
they are closely correlated in normal and pathogenic conditions, likely due to the fact that NE and DA are on the
same biosynthesis pathway.
Parkinson’s disease (PD) is a neurodegenerative disease in which both the noradrenergic and dopaminergic
systems share a progressive neuronal loss. Nevertheless, a
number of studies have showed that a constant and
extensive neuronal loss in the LC of PD patients is
even greater than loss of dopaminergic neurons, and
this pathology appears earlier to the dopaminergic neuronal loss in the SN (Cash et al., 1987; Bertrand et al.,
1997; Zarow et al., 2003). Recent observation showed
that a transgenic mouse, expressing human wild-type
a-synuclein controlled by dopamine b-hydroxylase
(DBH) promoter, developed a-synuclein in LC neurons
with degeneration of LC fibers, decreased striatal DA
metabolism, and non-motor symptoms of PD
(Butkovich et al., 2020). Therefore, NE deficiency is an
early indication of PD progression in the brain (Espay
et al., 2014). Moreover, LC-NE pathologies are directly
associated with the severity of parkinsonism, including
cognitive inflexibility (McGaughy et al., 2008). More
importantly, an intact LC-NE neuronal system has neuroprotective effects on dopaminergic neurons and an
increased NE concentration in the brain can facilitate
the recovery of the damaged dopaminergic system
(Delaville et al., 2011; Isaias et al., 2011; ParedesRodriguez et al., 2020). Therefore, restoration of the
damaged central LC-NE system may positively influence
the recovery process of degeneration to the dopaminergic
system, ultimately facilitating the treatment of PD.
Over the past several years, substantial progress has
been made in uncovering critical effects of transcription
factors such as Phox2a, Phox2b, Hand2 and Gata3 on
the brain’s noradrenergic system. It is well known that
during the embryonic period, these transcription factors
coordinately control the differentiation of noradrenergic
neurons (Brunet and Pattyn, 2002; Schmidt et al., 2009;
Tsarovina et al., 2010). Recent studies also revealed that
these transcription factors have potential regulatory roles
for noradrenergic properties in the adult brain.
Supportive evidence includes that all four transcription
factors are present in fully differentiated noradrenergic
neurons in vitro and in noradrenergic neurons in the
brain throughout life (Zhu et al., 2005; Doxakis et al.,
2008; Zhao et al., 2008; Schmidt et al., 2009; Pellegrino
et al., 2011). Furthermore, they are required for maintenance of mature noradrenergic neurons in vivo and for
the continued expression of DBH and tyrosine hydroxylase (TH) (Lucas et al., 2006; Schmidt et al., 2009; Card
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et al., 2010; Tsarovina et al., 2010). Our previous studies
in vitro and in vivo showed that these transcription factors
could increase the transcription of DBH and TH (Fan
et al., 2009; Fan and Zhu, 2010; Fan et al., 2011).
Therefore, it is feasible to enhance the function of the
noradrenergic system in PD animal models by overexpressing these transcription factors in the LC.
The neural specific vesicular monoamine transporter 2
(VMAT2) is a transmembrane protein and is a key regulator of monoamine homeostasis. VMAT2 plays an
important role in monoamine storage, protects neurotransmitters from oxidation and controls quantal secretion of these neurotransmitters (Erickson et al., 1992). As
such, loss of VMAT2 function has been considered to be
conductive to the pathology of PD (Lotharius and
Brundin, 2002). A transgenic mouse (called as VMAT2
Lo) has been created with 95% shutdown in endogenous VMAT2 expression (Mooslehner et al., 2001;
Colebrooke et al., 2006). These mice display substantial
reductions of DA and NE levels in the striatum and
cortex, and progressive degeneration in dopaminergic
and noradrenergic neurons with formation of
a–synuclein containing inclusions in the SN (Caudle
et al., 2007; Taylor et al., 2009, 2011). This model also
shows motor- and non-motor symptoms with the VTA
unaffected, thereby replicating important pathogenic features of PD. More importantly, unlike other chemical
and genetic models of PD, neuronal loss in the LC of
VMAT2 Lo mice starts earlier (at 12 months, and with
a larger reduction at 18 months of age) than occurs in the
SN (beginning at 18 months and reaching significant
degeneration at 24 months and maximal severity at
30 months) (Caudle et al., 2007; Taylor et al., 2014).
Furthermore, the LC undergoes a much more severe
degeneration than the SN in the VMAT2 Lo mice
(Taylor et al., 2011, 2014). Therefore, these mice are an
excellent model for the analysis of restoring noradrenergic activity and further affecting the dopaminergic
system.
In the present study, effects of forced overexpression
of transcription factors on activities and function of central noradrenergic and dopaminergic systems were examined. The lentiviral construction cassettes of Phox2,
Hand2 and Gata3, alone or combined, were microinjected into the LC region in VMAT2 Lo mice. The
expression levels of noradrenergic and dopaminergic phenotypes in brain areas were measured. The results demonstrated that overexpressed transcription factors
upregulated DBH and TH expression in the LC and its
main projection areas, and increased NE/DA concentrations in the striatum. Furthermore, these treatments also
enhanced TH expression in the SN and striatum and
improved cognitive and locomotor performance. These
data indicate that microinjection of these transcription
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factors can be an alternative approach for gene therapy
in PD.

Method and Materials
Lentiviral Vector Production
Lentiviral vectors were prepared and used by the similar
methods as published previously (Fan et al., 2011), which
was approved by the Institutional Biosafety Committee
of the East Tennessee State University. Briefly, a lentiviral vector pLenti6/V5, and the packaging vector
pCMV䉭R8.9 and pVSVG were used in this preparation.
Dual promoters to drive the genes of interest (Phox2a,
Phox2b, Hand2 or Gata3 from mice), and the reporter
gene (enhanced green fluorescent protein, eGFP), an
index for verification of viral delivery to the LC site in
mouse brains, were constructed as lentiviral-mediated
expression cassettes, based on the manufacturer’s instruction (Invitrogen, Carlsbad, CA, USA). The cassette for
the control in the experiments contained eGFP only.
After modification, transferring, co-infection, and untracentrifugation, the lentiviral stock was obtained and their
viral titers were measured. A stock with viral titer (1x108
TU) was stored at 80 C until use.

Animals and in Vivo Stereotaxic Microinjection
Both male and female VMAT2 Lo mice (RRID:
MGI_3758030), bred in the animal facility of the XXX
State University, were used in the present study. As
described above, neuronal loss in the LC of VMAT2
Lo mice starts at 12 months, and with a larger reduction
at 18 months of age (Taylor et al., 2014). Considering
these characteristics, two ages of mice were selected for
microinjection treatments: 12 months of age (the LC
begins degeneration), and 18 months of age (significant
LC neuronal loss and dopaminergic neurons in the SN
beginning to degenerate). Although VMAT2 Lo mice at
24 month of age showed more severely neuronal loss in
the SN with major motor deficits, they were determined
to be of too advanced age to bear the microinjection
surgery based on preliminary observations. Tissues
were used without regard to the sex of the animal so
we are unable to assess sex-dependent effects.
These mice were housed on a 12 h light/dark cycle and
had free access to food and water. All animal handling
procedures were approved by the Animal Care and Use
Committee of East Tennessee State University, which are
consistent with the NIH Guide for the Care and Use of
Laboratory Animals (National Research Council, 2011).
VMAT2 Lo and age-matched wild-type littermates were
randomly assigned to the experimental and control/
sham-operation groups. The animal numbers used in
groups were estimated by a power analysis. This is
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based on our preliminary studies, by assuming the
weaker of the two effects (i.e., Post-BUP).
Microinjection was performed based on previous works
(Carlezon and Neve, 2003) with some modifications.
Briefly, under gas anesthesia through isoflurane (1.5–
2.0%), animals were placed in a stereotaxic apparatus
(David Kopf Instruments, Tujunga, CA). Two burr
holes were drilled into the skull above the LC region
with an electric hand-drill to the level of the dura
mater. A sterile 26-guage Hamilton syringe, loaded
with recombinant lentivirus preparations (1 ml at 1  108
TU of titer per milliliter, or 2 ml in the combination of
two genes), was lowered to the LC ([AP] ¼ 5.4 mm,
[LAT] ¼ 0.9 mm, and [V] ¼ 3.9 mm) (Paxinos and
Franklin, 2001). Microinjection was carried out at a
rate of 0.1 ml/30 seconds over a period of 10 minutes
(20 min in the combination of two genes: either
Phox2aþHand2, Phox2bþGaba3, or Phox2bþHand2,
Phox2bþGaba3). After injection, dental cement was
used to fill the holes and the incision closed with sutures.
In the control mice, the lentiviral cassette carrying eGFP
only was bilaterally microinjected, whereas in shamoperated mice an empty Hamilton syringe was lowered
into the LC region without injection. Mice given surgery
were allowed to recover, and 21 days later were sacrificed
by decapitation (for biochemical measurements) or perfusion (for immunofluorescence staining). After decapitation mouse brains were removed, rapidly frozen in 2methyl-butane on dry-ice, and stored at 80 C until dissection of different brain regions (see below for the
details of the LC dissection). Perfused mouse brains
were also stored at 80 C until section on a cryostat.
To protect newly synthesized NE and DA, the noselective monoamine oxidase inhibitor phenelzine
(10 mg/kg, i.p.) (Griebel et al., 1998; Dwivedi et al.,
2006; Sakata et al., 2013) was administered daily for
21 days for all VMAT2 Lo mice (except for those without
injected mice), as well as corresponding control and
sham-operation groups. Microinjection into the LC
region was verified by examining eGFP fluorescence
under a fluorescence microscope to confirm the delivery
of the viruses to the LC region. Mice with missed placements were eliminated from the study.

RNA Isolation and Quantitative Real-Time Polymerase
Chain Reaction (qPCR) Analysis for mRNAs of Phox2a,
Phox2b, Hand2, Gata3, TH and DBH in the LC
The brains of some mice were microdissected at 20 C.
First, along the line between the posterior border of the
cerebral cortex and cerebellum was vertically cut with a
razor blade to separate the brain stem from the brain
cortex to show the midbrain aqueduct. Then a slight
trimming to sure the appearance of the 4th ventricle,
which was used for orientation of the LC. From there a
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posterior section from appearance of 4th ventricle to the
place where the 4th ventricle becomes a triangle shape a
section of about 350 mM thickness was cut again (approximately 5.34 to 5.70 mm from the Bregma). On this
coronal section a 2 mm trephine tool was used to punch
the LC region near two corners of the 4th ventricle. The
LC tissues were collected and stored at 80 C for RNA
isolation. The RNA isolation and qPCR analysis were
similar to those described previously (Zha et al., 2011).
Briefly, RNAzol reagent (Molecular Research Center,
Inc., Carlsbad, CA) was used to extract total RNA
from dissected brain LC regions of mice. The superscript
III First-Strand Synthesis Kit (Applied Biosystems/Life
technologies, Forster City, CA, USA) was used to convert cDNAs, based on the manufacturer’s protocol. Then
qPCR analysis was performed using primers listed as
follows. Mouse DBH: 50 - CTCAGGAGACTGCCTTT
GTGTTG-30 and 50 - GAAGCTGAGAGGCAAAGAT
GTGG-30 . Mouse TH: 50 -AGCCGTGCAGCCCTACC
A-AGATCAA-30 and 50 - AATGGGCGCTGGATACG
AGAGGCAT-30 ; Mouse Phox2a: 50 -CGAGGAACTGG
CGCTCAAGA-30 and 50 - CGCTCCTGTTTGCGGAA
CTTG-30 ; Mouse Phox2b: 50 -GGGCTAAGTTTCGC
AAGCAG-30 and 50 - CAGTGCTGTCGGGATCAG
TG-30 ; mouse b-actin: 50 -CAACGAGCGGTTCCGA
TG-30 and 50 - GCCACAGGATTCCATACCCA-30 .
For analyzation of the relative changes in gene expression from qPCR, the value of each interest gene was normalized to b-actin (DCt). The comparative threshold
cycle method (2DDCT) (Livak and Schmittgen, 2001)
was used to compare mRNA levels of each respective
gene expression calculated as the inverse log of DDCT
to give the relative fold change. These measurements
were performed in triplicate of each cDNA aliquot.

Immunofluorescence Staining for DBH and TH
This method was similar to previous work from our laboratory (Fan et al., 2011). Briefly, the slides containing
the sections of LC regions were pre-incubated in 5%
bovine serum albumin in phosphate-buffer saline (PBS)
supplemented with 0.2% Triton-X 100. These slides were
further exposed to primary monoclonal antibody solution (for DBH: 1:2000, ab19353, RRID: AB_73185,
Abcam, Cambridge, MA, USA; for TH: 1:1000, MA124654, RRID: AB_79566, ThermoFisher Scientific,
Waltham, MA, USA) overnight at 4 C. After washing,
slides were then probed with 2nd antibodies (for DBH:
Alexa Fluor 488-conjugated goat anti-rabbit IgG; for
TH: Alexa Fluor 488-conjugated Goat anti-mouse IgG;
both from Abcam, Cambridge, MA, USA), followed by 4
time rinses with 0.1 M PBS. A Leica TCS SP2 confocal
microscope
system
(Leica
Microsystems
Inc.,
Bannockburn, IL, USA) was used to observe and acquire
immunofluorescence labeling. These images were
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quantitatively quantified using ImageJ software
(Rasband, US National Institutes of Health, Bethesda,
http://rsbweb.nih.gov/ij, 2010). Non-immunoreactive
portions of brain sections adjacent to the LC region
were taken as the reference background levels.

Measurement of NE/DA by High-Performance Liquid
Chromatography (HPLC)
Measurement of NE/DA in mouse striatum was similar
to those described before (Fan et al., 2020). Briefly, animals were sacrificed and brains were dissected. The striatum was homogenized in an ice-cold solution containing
0.2 M perchloric acid, 1  107 M ascorbic acid, and
dihydroxybenzylamine (2 mg/ml) which was used as the
internal standard. Following centrifugation (10,000 xg at
4 C for 5 minutes) and filtration in 0.2 mm nylon disposable syringe filters, the supernatant (5 mL) was injected
into the HPLC system. This chromatography system
includes an Ultrasphere ODS reverse-phase column
(Beckman), electrochemical detection and a Hitachi D2500 Chromato-Integrator. The mobile phase consisted
of 4% acetonitrile, 0.1 M sodium nitrate, 0.08 M sodium
dihydrogen phosphate, 0.2 mM sodium octyl sulfate, and
0.1 mM EDTA. A standard curve was constructed with
known amounts of NE/DA to calculate the NE/DA concentration. Before centrifugation and filtration, the protein concentration in tissue homogenate of the striatum
was measured, which was used to define the NE/DA presentation in homologies as pg/mg proteins.

Behavior Tests: Morris Water Maze (MWM) &
Locomotor Behavior Tests
The MWM is a behavior test for animal spatial learning
and reference memory and the method used for this task
was similar to previous work (Brown et al., 2001).
Briefly, animals were administered a total of 4 days of
testing. Each day two trial blocks of four trials were
given to each animal, for a total of 24 training trials
during acquisition. On each trial, mice were released
with their snout pointing towards the wall of the pool
in the east, north, south and west (these directions do not
indicate compass points) quadrants of the pool and
allowed a swim time of 60 s to reach the platform. If
the mouse did not find the platform, it was placed
there by the experimenter. Regardless, if the animal
found the platform, it spent the last 10 s of each trial
on the platform. Both swim distance and escape latency
(time to find the platform) were recorded on each trial.
Following the last trial, the platform was removed from
the pool and a probe trial was administered. For the
probe trial, the mean search difference (MSD) and
mean search difference (MZD) scores (Brown et al.,
2000; Gonzalez et al., 2000) were used to analyze
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search behavior. The total time spent searching and swim
pattern was recorded via a digital camera (Rockhouse
Products,
NJ,
USA).
The
AnyMaze
behavioral scanning system (Stoelting, Co, Wood
Dale, IL, USA) was used to analyze all behavioral
measurements.
The locomotor activity test is a mean of assessing
spontaneous locomotor activity and arousal in mice,
and is necessary to establish baseline levels of motor
activity. The method used was similar to a previous publication (Brown et al., 2011). Briefly, animals were placed
individually in a square arena (30 cm/side) with Plexiglas
floor and walls (Kinder Inc., Poway, CA, USA) and
allowed to freely move for 60 min. All animal locomotor
activities were recorded by the AnyMaze behavioral software and distance traveled during the 60 min period was
recorded and analyzed.

Western Blot Analysis
Western blotting was performed similar to previous work
from our laboratory (Fan et al., 2011). About 30 mg proteins from each sample were loaded into a 10% SDS–
polyacrylamide gel and electrophoretically separated,
and electro-blotted onto a nitrocellulose membrane
(Amersham Life Sciences, Buckinghamshire, UK).
These blots were respectively incubated with antibodies
of monoclonal anti-TH antibody (H-16, 1:1,000 dilution,
AMAb91112, RRID: AB_2665805, Sigma, USA), or
monoclonal antibody against DBH (sc-365710, 1:100
dilution,
RRID:
AB_1084404,
Sanda
Cruz
Biotechnology, Dallas, TX, USA), which was followed
by being exposed to the second antibody (1:5,000 dilution; Amersham Life Sciences, Buckinghamshire, UK).
Immunoreactive bands were visualized and detected by
G:Box Imaging (Fyederick, MD, USA) after membranes
were probed by enhanced chemiluminescence (ECL,
Amersham Life Sciences, Buckinghamshire, UK) or
super ECL (Sigma Chemical Co., St Louis, MO, USA).
By the similar steps, ß-actin reactivates were determined
as an index of equal loading and transfer effectivities
after membranes were re-probed using antibody against
mouse ß-actin.
Statistics: All experimental data are presented in the
text and graphs as the mean  SEM, with an enumerated
replicate number (N ¼ x/group) in the figure legends.
Statistical analysis was carried out using one-way analysis of variance (ANOVA) when comparing multiple treatment groups for most experiments (SigmaStat, Systat
Software Inc., Richmond, VA). Then post-hoc
Duncan’s Multiple Range tests were performed for
planned comparisons. A two-way ANOVA was used
for MWM acquisition statistics.
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Results
Microinjection of Lentiviral Expression Cassettes
Enhanced mRNA Levels of Phox2a/2b, DBH and
TH in the LC Region
The cassettes of recombinant lentiviral vector-cDNAs
(Phox2a or Phox2b, plus Hand2 or Gata3) were bilaterally
microinjected into the LC region of VMAT2 Lo mice. Agematched wild-type littermates were used as the control
(microinjected with lentiviral constructs containing eGFP
only) and sham operation groups (an empty Hamilton
syringe lowered into the LC region without injection). All
mice were sacrificed on the 22nd day after microinjection, a
period that long enough for overexpression of transcription
factors based on past works (Fan et al., 2011). Figure 1A
showed that microinjection was accurately delivered to the
LC region as indicated by eGFP fluorescence in the target
area. The first experiment was to examine mRNA levels of
Phox2a/2b, Hand2 and Gata3 in these mice by quantitative
PCR (qPCR). As shown in Figure 1B and C, microinjection
of these lentiviral expression cassettes significantly influenced mRNA levels of Phox2a and Phox2b in the LC
regions (Figure 1A for Phox2a, 12 month: F6,64, ¼ 6.85,
p < 0.01; 18 month: F6,63 ¼ 4.18, p < 0.05. Figure 1B for
Phox2b, 12 month: F6,56, ¼ 9.25, p < 0.001; 18 month:
F6,58 ¼ 7.37, p < 0.01). Comparison of the control and
sham-operation groups showed no significant difference,
indicating microinjection operation did not cause marked
effects on these gene expressions. The comparison results
for the control and sham-operation groups were similar for
all following experiments. Post hoc analysis revealed that
whereas both control and sham-operated groups demonstrated a significantly higher Phox2a mRNA expression
than those in VMAT2 Lo mice without microinjection
(Lo) (p < 0.05 or 0.01 respectively), microinjection of
Phox2a, Phox2aþHand2 and Phox2aþGata3 resulted in
a markedly increased Phox2a mRNA level (p < 0.01), as
compared to those of Lo mice. However, there was no significant difference between these microinjection groups and
control groups (Figure 1A). A similar expressive pattern
was found for Phox2b mRNA measurements (Figure
1B). Similarly, microinjection of these cassettes also markedly influenced mRNA levels of Hand2 and Gata3 in the
LC (Figure 1D for Hand2, 12 months: F6,64, ¼ 5.33,
p < 0.01; 18 month: F6,63 ¼ 5.24, p < 0.01. Figure 1E for
Gata3, 12 month: F6,56, ¼ 6.78, p < 0.01; 18 month:
F6,58¼6.27, p < 0.01). It is noteworthy that comparing to
those in the control, there are a relatively lower expression
level of Phox2a or Phox2b in the LC in Lo mice of both 12
and 18 month-old, and relatively lower levels of Hand2 and
Gata3 in the LC of 18 month-month. It indicates that in
VMAT2 Lo mice the expression of these transcription factors was also reduced accompanied with the loss of noradrenergic neurons.
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Figure 1. Effects of microinjection on mRNAs of Phox2a/2b, Hand2 and Gaba3 in the LC region as indicated by eGFP fluorescence in the
target area. mRNA expression levels of Phox2a (A), Phox2b (B), Hand2 (C) and Gata3 (D) in the LC of 12 or 18 month-old mice after
microinjection of lentiviral expression cassettes, measured by qPCR (N ¼ 6). * p < 0.05, ** p < 0.01, compared to the Lo. † p < 0.05,
compared to the control. Scale bar ¼ 100 mm in (A). Abbreviations: Con: control; Sham: sham-operation; Lo: VMAT2 Lo mice without
microinjection; 2a: microinjection with Phox2a; 2 b: microinjection with Phox2b; 2a/H or 2 b/H: microinjection with Phox2a or
Phox2bþHand2; 2a/G or 2 b/G: microinjection with Phox2a or Phox2bþGata3.

Next, mRNA levels of DBH and TH in the LC were
measured aiming to elucidate effects of over-expression
of these transcription factors on the noradrenergic phenotype. qPCR analysis showed that microinjection of
lentiviral expression cassettes markedly changed mRNA
levels of DBH and TH (Figure 2A for 12 month-old,
DBH: F8,54 ¼ 7.15, p < 0.01; TH: F8,54 ¼ 3.21, p < 0.05.
Figure 2B for 18 month-old, DBH: F8,52 ¼ 7.25,
p < 0.001; TH: F8,52 ¼ 6.53, p < 0.01). Post hoc analysis
demonstrated that in 12 month-old Lo mice, mRNA

levels of DBH and TH were not significantly different
from the control (Figure 2A), indicating a relatively
intact distribution of noradrenergic neurons at that
developmental period. However, in 18 month-old Lo
mice (Figure 2B), mRNA levels of DBH and TH were
markedly reduced as compared to those in the control, a
consistent finding with previous work (Taylor et al.,
2014). In the LC of 12 month-old VMAT2 Lo mice,
a significantly increased DBH mRNA level was found
in
the
groups
microinjected
with
Phox2b,

Cui et al.

Figure 2. Effects of microinjection on mRNAs of DBH and TH in
the LC of 12 or 18 month-old mice after microinjection of lentiviral
expression cassettes, measured by qPCR (N ¼ 6). *p < 0.05,
**p < 0.01, compared to the Lo. †p < 0.05, compared to the control. See Figure 1 legend for abbreviations. 12-m or 18-m: 12 or
18 month-old mice.

Phox2aþHand2, Phox2bþHand2 and Phox2bþGata3,
respectively, as compared to Lo animals. Interestingly,
DBH mRNA levels in the group of microinjection of
Phox2b,
Phox2aþHand2,
Phox2bþHand2
and
Phox2bþGata3 were even higher than those of the control (Figure 2A). Whereas microinjection of
Phox2bþHand2 increased TH mRNA levels, other
groups did not show a statistical difference at 12 months
of age, as compared to the Lo group (Figure 2A).
Nevertheless, in 18 month-old mice, all microinjection
groups showed an enhanced mRNA level of DBH or
TH in the LC, as compared to those Lo mice (Figure
2B, p < 0.05 or p < 0.01).

Microinjection of Lentiviral Expression Cassettes
Increased Protein Levels of DBH and TH in the
LC Region
Immunofluorescence analysis was used to measure protein levels of DBH and TH in the LC after microinjection
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of lentiviral expression cassettes in the brain of 12 and
18 month-old mice. Our previous study demonstrated
that protein levels of DBH and TH in the LC as measured by immunofluorescence staining and western blotting were very similar (Fan et al., 2020). Therefore, only
immunofluorescence staining was used for DBH and TH
proteins in the LC in the present study. As shown in
Figure 3, overexpression of transcription factors in the
LC significantly affected DBH protein levels in the LC
(12 month-old: F8,54 ¼ 4.15, p < 0.05; 18 month-old:
F8,63 ¼ 6.78, p < 0.01). DBH immunoreactivities in the
LC of 12 month-old Lo mice were not markedly different
from those of the control. However, 18 month-old Lo
mice exhibited a markedly reduced DBH immunoreactivities as compared to those of control (p < 0.01,
Figure 3B), indicating a severe loss of noradrenergic
neuron in the LC of 18 month-old VMAT2 Lo mice.
Post hoc analysis demonstrated that in the LC of
12 month-old mice, the microinjection of all injected
groups produced a significant increase of DBH immunoreactivities, as compared to those of the control
(Figure 3A). In the LC of 18-month-old mice, whereas
all VMAT2 Lo mice microinjected with lentiviral expression cassettes showed a marked enhanced DBH immunoreactivities than those in the Lo mice, DBH
immunoreactivities in the groups microinjected with
Phox2aþHand2, and Phox2aþGata3 were higher than
those in the control group (p < 0.05) (Figure 3B).
The TH immunofluorescence staining in the LC also
showed similar results as those of DBH. Compared to the
control, TH immunoreactivity in the LC of Lo mice at
the age of 12 month-old were not significantly reduced,
but those of Lo mice at 18 month-old did show a reduction compared to the control (Figure 4). Microinjection
of lentiviral expression cassettes highly influenced the TH
immunoreactivity in the VMAT2 Lo mice (12 month-old:
p < 0.01;
18 month-old:
F8,62 ¼ 7.88,
F8,64 ¼ 5.65,
p < 0.01). Post hoc tests revealed that where TH immunoreactivity in all microinjection groups were markedly
higher than those of Lo mice (p < 0.05 or p < 0.01), they
were also significantly higher than those of the control in
12 month-old VMAP2 Lo mice (p < 0.05 or 0.01). In mice
of 18 month-old, LC TH immunoreactivities after microinjection of Phox2a/2bþ Hand2 or Gata3 were higher
than those of the control (p < 0.01, Figure 4B).

Microinjection of Lentiviral Expression Cassettes
Increased Protein Levels of DBH and TH in Other
Brain Regions
In the brain the LC is the primary source of noradrenergic projections to the FC and HP. Therefore, DBH protein levels in these regions were measured by western
blotting. As shown in Figure 5, DBH protein levels in
the FC and HP of 12 month-old Lo mice were not
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Figure 3. Effects of microinjection on DBH proteins in the LC after microinjection of lentiviral expression cassettes measured by
immunoflurescence in mice at age of 12 month-old (N ¼ 6) (A) and 18 month-old (N ¼ 5) (B). Upper panels in A and B are representative
micrographs of DBH immunofluorescence. Lower panels in A and B: quantitative analysis of DBH immunofluorescence. *p < 0.05,
**p < 0.01, compared to the Lo mice; †p < 0.05, compared to the control. See Figure 1 legend for abbreviations. 12-m or 18-m: 12 or
18 month-old mice. Scale bar: 25 mm for all images.

significantly changed compared to the control. Further,
microinjection of lentiviral expression cassettes markedly
influenced DBH protein levels in these two regions
in VMAT2 Lo mice at 12 and 18 month-old ages
(Figure 5A: 12 month-old FC: F8,64 ¼ 3.55, p < 0.05;

18 month-old FC: F8,62 ¼ 5.78, p < 0.01. Figure 5B:
12 month-old HP: F8,56 ¼ 3.75, p < 0.05; 18 month-old
HP: F8,60 ¼ 5.97, p < 0.01). Post hoc tests demonstrated
that in the FC (Figure 5A) of 12 month-old VMAT2 Lo
mice microinjection of Phox2b and Phox2bþHand2
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Figure 4. Effects of microinjection on TH proteins in the LC. after microinjection of lentiviral expression cassettes (N ¼ 6) measured by
immunoflurescence in mice at age of 12 month-old (A) and 18 month-old (N ¼ 5) (B). Upper panels in A and B are representative
micrographs of TH immunofluorescence. Lower panels in A and B: quantitative analysis of TH immunofluorescence. *p < 0.05, **p < 0.01,
compared to the Lo mice † p < 0.05, compared to the control. See legends of Figures 1 and 2 for abbreviations. Scale bar: 25 mm for all
images.

significantly increased DBH protein levels (p < 0.05).
However, although DBH protein levels in all microinjection groups in 18 month-old mice were higher than those
in Lo mice, only those microinjected with Phox2a,
Phox2aþGata3, and Phox2bþGata3 reached statistical

significances (p < 0.05). In the HP (Figure 5B),
12 month-olds that received microinjection of Phox2a
and Phox2aþGata3 markedly enhanced DBH protein
levels, as compared to those in Lo mice. In the
18 month-old groups, microinjection of Phox2a and
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Figure 5. Effects of microinjection on DBH proteins in the FC and
HP (A) and hippocampus (B) of mice measured by western blotting
(all N ¼ 5). The upper panels in A and B show autoradiographs
obtained by western blotting. The lower panels in A and B show
quantitative analysis of band densities. *p < 0.05, **p < 0.01, compared to the Lo mice. See legends of Figures 1 and 2 for
abbreviations.

Figure 6. Effects of microinjection on DBH proteins in the striatum and SN (A) and substantia nigra (SN, B) of mice measured by
western blotting (all N ¼ 5). The upper panels in A and B show
autoradiographs obtained by western blotting. The lower panels in
A and B show quantitative analysis of band densities. *p < 0.05,
**p < 0.01, compared to the Lo mice. See legends of Figures 1 and
2 for abbreviations.

Phox2bþGata3 significantly increased DBH protein
levels (p < 0.05 or p < 0.01), although DBH levels in all
injection groups were higher than those of Lo mice
(Figure 5B).
The striatum and SN are the major regions where
dopaminergic neuron are distributed in the brain. To
assess effects of overexpression of transcription factors
in the LC on dopaminergic neurons, TH protein levels,
as a dopaminergic phenotype, in these regions were
examined. Compared to the control, TH protein levels
of the striatum (Figure 6A) and SN (Figure 6B) in Lo
mice of 12 month-old mice were not significantly changed
(p > 0.05). However, 18 month-old Lo mice exhibited a
significantly reduced TH protein level in these two brain

areas (p < 0.05). Microinjection of lentiviral expression
cassettes markedly influenced TH levels in these two
regions (Figure 6A: 12 month-old striatum: F8,59 ¼ 3.78,
p < 0.05; 18 month-old striatum: F8,64 ¼ 6.48, p < 0.01.
Figure 6B: 12 month-old SN: F8,60 ¼ 4.28, p < 0.05;
18 month-old SN: F8,64 ¼ 6.17, p < 0.01). Post hoc tests
revealed that in 12 month-old VMAT2 Lo mice, microinjection of Phox2a and Phox2bþHand2 markedly
enhanced TH protein levels in the striatum (p < 0.05).
In 18 month-old VMAT2 Lo mice, all microinjection
groups showed a significant increase of TH levels in the
striatum, as compared to those in Lo mice (p < 0.05 or
p < 0.01, Figure 6A). In the SN, there were an enhanced
TH protein level in microinjection of Phox2b and
Phox2aþGata3 in 12 month-old mice, and microinjection
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of Phox2a, Phox2aþHand2 and Phox2aþGata3 exhibited an increased TH protein level in 18 month-old mice
(P < 0.05, Figure 6B).

Microinjection of Lentiviral Expression Cassettes
Increased NE/DA Levels in the Striatum
To examine effects of overexpression of transcription factors in the LC on noradrenergic and dopaminergic transmitters in the brain, NE and DA concentrations in the
striatum of VMAT2 Lo mice and littermates were measured by HPLC using similar methods as previous work
(Fan et al., 2020). In both 12 and 18 month-old Lo mice,
NE and DA concentrations in the striatum were significantly reduced, as compared to those in the control
(p < 0.01), a consistent finding to previous report
(Taylor et al., 2014). As shown in Figure 7, microinjection of lentiviral expression cassettes significantly
affected NE/DA concentrations in the mouse striatum
(Figure 7A: 7 to 12 month-old: NE: F8,54 ¼ 7.89,
p < 0.01; DA: F8,54 ¼ 7.23, p < 0.01. Figure 7B:
18 month-old:
NE:
F8,52 ¼ 5.23, p < 0.01; DA:
F8,52 ¼ 7.68, p < 0.01). Post hoc tests demonstrated that
although NE concentrations in the striatum in all groups

Figure 7. Effects of microinjection of lentiviral expression cassettes on NE/DA levels in the striatum measured by HPLC (all
N ¼ 6) in 12 (A) and 18 month-old (B) mice. *p < 0.05, **p < 0.01,
compared to the Lo mice. See Figure 1 legend for abbreviations.
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of 12 month-old and 18 month-old VMAT2 Lo mice were
much lower than those in the control or sham groups,
they were markedly higher than those in the Lo mice
(p < 0.05). Similar results were revealed for DA concentrations in the striatum in all groups of 12 month-old
(Figure 7A) and in three groups of 18 month-old
VMAT2 Lo mice (microinjection of Phox2a, Phox2b
and Phox2aþHand2 (P < 0.05 or 0.01, Figure 7B). The
increased NE/DA concentrations in the striatum indicate
that overexpression of transcription factors in the LC
improved upon a significantly degenerated noradrenergic
and dopaminergic system, although the levels of NE and
DA were significantly lower than those of controls.

Microinjection of Lentiviral Expression Cassettes
Altered Cognitive and Locomotor Behavior
The MWM behavioral test was performed in these PD
model mice. The acquisition latency and mean search
difference (MSD) were used to judge effects of overexpression of transcription factors in the LC on cognitive
behavior. A two-way ANOVA was used for the statistics
of accusation in which the treatment and trial block were
two effectors. The analysis revealed that a significant
main effect of treatment (F1,70 ¼ 9.11, p < 0.001), trial
block (F1,70 ¼ 47.43, p < 0.001), and a significant interaction of treatment x trial block (F1,70 ¼ 2.92, p < 0.04.
Both controls and sham groups demonstrated significant
lower latencies than all other groups from trial blocks
through 5, especially compared to Lo group (ko mice).
As shown in Figure 8A and B, Lo mice in both 12 and
18 month-old exhibited a longer acquisition latency and
lower MSD scores, as compared to those in the control,
indicating a cognitive deficit, and it should be noted that
there were no significant differences in swim speed (m/s)
across groups. In 12 month-old VMAT2 Lo mice, microinjection with Phox2aþGata3 markedly improved acquisition latency performance (p < 0.05) from trial blocks 3
to 5, and microinjection with Phox2bþGata3 also
improved acquisition latency in trial block 5, as compared to Lo mice (Figure 8A).
In
addition,
microinjection
with
Phox2b,
Phox2a þ Gata3 and Phox2bþGata3 markedly increased
MSD scores on the probe trial (F8,44¼3.87, p < 0.05), as
compared to those in Lo mice (Figure 8B), indicating
improvement of search behavior for the platform. In
18 month-old mice, microinjection with Phox2a,
Phox2aþHand2 and Phox2bþGata3 significantly
reduced acquisition latency (p < 0.05). Also, except for
the microinjection with Phox2b, all other groups
showed a significantly increased MSD score (F8,44 ¼
4.52, p < 0.05), compared to the Lo mice (Figure 8D).
These results demonstrated that overexpression of specific transcription factors in the LC ameliorated deficits
in spatial memory performance without disrupting swim
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Figure 8. Behavior tests, Effects of Microinjection of Lentiviral Expression Cassettes on Mouse Behavior Performance Measured by
MWM or Locomotor Tests (N ¼ 5). Acquisition latency (A, B) is represented as a function of trial blocks. Trial blocks consisted of four
training trials each. Mean search difference scores (C, D) are represented as a function of group. Distance traveled is represented as the
locomotor test result in 12 month-old (E) and 18 month-old (F). *p < 0.05, **p < 0.01, compared to the Lo mice. See legends of Figures 1
and 2 for abbreviations.

speed, indicating that cognitive function appears to have
been improved in microinjected VMAT2 Lo mice.
For locomotor activities, as shown in Figure 8E and
F, Lo mice in both 12 and 18 month-old showed a significant reduction in distance traveled (p < 0.05 or
p < 0.01). Microinjection of Phox2a þ Hand2, Phox2a þ
Gata3 and Phox2b þ Gata3 in 12 month-old mice, as well
as all microinjected groups except for Phox2b groups in
18 month-old mice demonstrated no change in locomotor
activity. Therefore, it appears that several manipulations

of these transcription factors alleviated spontaneous
motor deficits due to knock-down of VMAT2.

Discussion
This study is an extension of our previous investigations
in adult and aged rats (Fan et al., 2011, 2020). In the
present study, VMAT2 Lo mice, a mouse PD model at
ages of 12 or 18 month-old, were microinjected with
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transcription factors Phox2a/2b or their combination
with Hand2 or Gata3 in the LC for 3 weeks to determine
whether these manipulations influence expression levels
of noradrenergic and dopaminergic phenotypes in the
brain. The results showed that after microinjection,
mRNA levels of Phox2a/2b, as well as DBH and TH in
the LC were significantly increased, as compared to those
of Lo mice. Furthermore, protein levels of DBH and TH
in the LC, FC and HP, as well as TH protein levels in the
striatum and SN were markedly elevated. These upregulated gene expressions were accompanied by an increased
level of NE and DA in the striatum and an improved
cognitive and locomotor behavior. The current observations not only support our previous findings that overexpression of these transcription factors in the LC can
upregulate the expression of noradrenergic phenotypes,
but also provide the evidence that restoring a damaged
noradrenergic function can facilitate the recovery of
injured dopaminergic system.
VMAT2 Lo mice display substantial reductions of DA
levels in the striatum and cortex, and progressive neurodegeneration in the SN with formation of a–synuclein
containing inclusions (Taylor, 2014). This model also
shows progressive degeneration in the LC with deficits
in motor and non-motor phenotypes, thereby replicating
important pathogenic features of PD (Caudle et al., 2007;
Taylor et al., 2009, 2011). More interestingly, neuronal
loss in the LC of these mice begins at 12 months of age,
and with a larger reduction at 18 months of age, whereas
neuronal loss in the SN begins at 18 months and reaches
significant degeneration at 24 months and later (Caudle
et al., 2007; Taylor et al., 2014). Considering one of goals
of this study is to examine whether a restored noradrenergic system can bring improvement to damaged dopaminergic neurons, two age groups such as 12 and
18 month-old were selected for over-expression manipulation. The reason for the selection of these ages is based
on the consideration that at ages of 12 or 18 months, the
neuronal loss of noradrenergic or dopaminergic neurons
in the LC or SN should be just beginning to emerge and
at this stage PD model mice should have ability to repair
damaged neurons, if an appropriate strategy is provided.
The data showed that in VMAT2 Lo mice at age of
12 months the microinjection increased mRNA levels of
Phox2a/2b and DBH/TH, as well as increased protein
levels of DBH/TH in the LC and other brain regions
were generally higher than those in 18 month-old
groups. Furthermore, consistent with these effects, the
microinjections of these transcription factors raised
NE/DA concentrations in the striatum of 12 month-old
VMAT2 Lo mice which were also relatively higher than
those in 18 month-old mice. Moreover, mRNA levels of
DBH and TH in the LC induced by microinjection in
12 month-old mice, rather than 18 month-old mice,
were even higher than those in the control (Figure 2A).
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This comparison reveals that the interference strategy for
PD would get better benefit at the early stage.
In the present study the lentiviral expression constructs of Phox2a or Phox2b were bilaterally microinjected into the LC region in combination with
constructs of transcription factors Hand2 or Gata3 for
the goal to assess the synergistic effects of these transcription factors. The test is based on the fact that they work
as a complex co-transcriptional regulatory network to
strengthen transactivation of various genes (Howard,
2005) and interact in a combinatorial fashion as a transcription factor scaffold at the DBH promoter (Xu et al.,
2003; Howard, 2005). The consequence of synergistic
actions in combination of Phox2 and Hand2 (Howard
et al., 2000), or Phox2 and Gata3 (Lim et al., 2000;
Tsarovina et al., 2004) is the significant enhancement of
transcriptional activities at the promoters of noradrenergic marker genes (Xu et al., 2003; Pellegrino et al., 2011).
It resulted for instance in a 5-fold increase in DBH
expression than that with Phox2a alone (Rychlik et al.,
2003). However, our data showed although there was a
mild increase for DBH and TH in the LC, as well as
DBH and TH in other brain regions in some groups
microinjected with combination cassettes when compared
to those microinjections of Phox2a or Phox2b alone, this
increase did not reach statistical significance. It indicates
that an expected synergistic action did not occur.
Currently we do not have a satisfactory explanation for
this discrepancy between those findings in the literature
and the present study. One possible contribution is the
difference between in vitro and in vivo experiments.
Among those reports regarding the synergistic action
from Phox2 and Hand2 or Gata3, except for two reports
which were related to development in embryos (Lim
et al., 2000; Tsarovina et al., 2004), all other reports
were in vitro studies. To the best of our knowledge, the
present research is the first study in vivo to examine the
synergistic effects of these transcription factors.
Generally, there has been a growing body of evidence
defining the value of using cell culture as an appropriate
in vitro model in order to elucidate mechanisms associated with the in vivo. However, in vitro experiments may be
under non-physiological conditions, as in vivo there are
stronger capacities to buffer or interfere with the transactivity. Therefore, the interpretation for in vitro results
should be cautious. Nevertheless, a tendency towards the
synergism was observed in the present study and it
deserves further investigation.
Coincident with our previous study in rats, the present
observation demonstrated that microinjection of lentiviral expression cassettes in the LC improved MWM acquisition and probe trial performance, indicating an
advancement in cognitive behavior in the microinjected
VMPT2 Lo mice. In addition, the current study showed
an ameliorative locomotor activity. Accompanying DA
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reduction, significant depletion of NE (>80%) in different brain regions was reported in the postmortem PD
brain (Taquet et al., 1982) due to the neuronal loss in
the LC (Freed, 1990; Zarow et al., 2003). In a consequence, progressive cognitive disturbances such as
memory loss, impaired ability in learning, attention and
decision making are typical problems in PD (Baggio
et al., 2014). Animal studies showed that the reduction
of these neurotransmitters leads to the functional deficits
in frontal cortex functions, including cognitive inflexibility (Tait et al., 2007; McGaughy et al., 2008). A locomotor deficit is an important hallmark of PD and most PD
models have reduced locomotor activity (Taylor et al.,
2010). In PD mouse models treated with MPTP, the
degeneration of dopaminergic neurons was followed by
a marked reduction of locomotor (Colotla et al., 1990;
McNaught et al., 1996; Zeng et al., 2014; Gratuze et al.,
2019). As showing in the present study, Lo mice exhibited
the similar cognitive and locomotor deficits (Figure 8),
possibly due to substantial reductions in NE/DA in the
brain as observed in the striatum in the present study and
reported in the literature (Taylor, 2014). Our study also
showed that overexpression of transcription factors in
the LC enhanced NE/DA concentrations in the striatum,
compared to those in Lo mice (Figure 7), as a result
parallel to upregulated noradrenergic and dopaminergic
phenotypes. An improved MWM and locomotor activity
results (Figure 8) fits relatively well with these alterations
in the brain, especially in 18 month-old groups. It has
been reported that stimulation of the noradrenergic
system or NE infusion enhance MWM acquisition
(Hatfield and McGaugh, 1999). In recently developed
transgenic mice expressing a-synuclein in the LC, adrenergic receptor antagonists rescued non-motor symptoms
of PD (Butkovich et al., 2020). A selective monoamine
oxidase B inhibitor L-deprenyl alleviated acquisition and
probe trial performance deficits caused by scopolamine
(Yavich et al., 1993; Gelowitz et al., 1994). Similarly, DA
antagonists impair MWM learning (McNamara and
Skelton, 1993) and transgenic mice lacking DA D1 receptors showed severely impaired MWM acquisition (Smith
et al., 1998); and administration of D1 receptor agonists
enhanced acquisition performance (Hersi et al., 1995).
Likely, administration of smilagenin (He et al., 2019) or
overexpression pre-enkephalin in the striatum
(Bissonnette et al., 2014) to increase TH positive neurons
in SN significantly improved the locomotor ability.
Therefore, enhanced noradrenergic and dopaminergic
activities resulting from overexpression of these transcription factors in the LC significantly improves the
function of the NE and DA systems. It consequently
improves behavioral performance, because both NE
and DA modulate the behavioral-affective components
of the whole-animal response (Antelman and Caggiula,
1977; Morilak et al., 2005).
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It is worthwhile to note that the Morris water maze is
well documented to be a hippocampal-dependent task
(D’Hooge and De Deyn, 2001). Compared to the TH
in the striatum and SN, in mice of 18- month-old the
effects of microinjection of expressional cassettes on
DBH in the hippocampus were not especially robust
although were higher than Lo group, and even were
not significant different from those of the controls,
expect for one group of “2a” (Figure 5B). However,
those groups that showed a significantly increased
DBH protein levels such as Phox2a in 18-month-old
and Phox2aþGata3 and Phox2bþGata3 in the hippocampus at age of 12 months, demonstrated an improvement on the latency (Figure 8B) and Mean Search
Difference score (MSD) of the probe trial (Figure
8C/8D). The probe trial, without the platform in the
pool, is an excellent measurement of spatial memory,
and has been argued to be more accurate relative to hippocampal integrity in past work (Whishaw et al., 1995).
The importance of the hippocampus in Morris water
maze performance, and especially on the probe trial of
this task demonstrates that these groups and enhanced
DBH positively correlate with spatial memory on this
task.
However, there is a discrepancy between behavior and
biochemical measures in some groups (Figure 8). While
this inconsistency between biochemical and behavioral
events has been reported in the literature, especially
when monoamine oxidase inhibitors were applied (Pani
et al., 1990; Blaha et al., 1996), this discrepancy may be
attributed by following reasons. First, the LC-NE system
is a critical component of the neural architecture. As
such, it appears reasonable to propose that dysfunction
of this system might contribute to the alteration in the
cognitive processes, and vice versa. However, the data in
the literature show some difference. For example, rats
with 6-OHDA-induced LC ablation did not show any
signs of impairment in learning tasks (Mason and
Fibiger, 1979). Furthermore, the noradrenaline uptake
inhibitor desipramine failed to improve learning and
memory impediment caused by the neurotoxin DSP4
(Ichihara et al., 1993). Similarity also happened to the
DA system: intra-cerebral injection of DA did not efficiently elicit behavioral changes (Costall and Naylor,
1975). Therefore, there is a notion that the LC-NE
system may be viewed as a general and global modulator
of neuronal circuits that guide behavioral action (Itoi,
2008; Itoi and Sugimoto, 2010). Second, behavioral
tests like the MWM is influenced by numerous factors,
including other transmitter systems (D’Hooge and De
Deyn, 2001). It may at least partly account for that
behavioral performances in PD animal models are more
complex than the change in gene expression and neurotransmitter levels. Finally, age may be another possible
effector. Mice at the age of 18 month are relatively old. It
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is reported that young and aged animal have different
effect in water maze performance (Sirvio et al., 1991).
It is documented that MWM performance declines with
increasing age of the animals (Brandeis et al., 1989).
Whereas more studies are needed to clarify correlation
between the behavioral alterations and gene overexpression, nevertheless, the present study provides some evidence for functional output of genetic manipulations in
this PD model.
It is well known that significant neuronal loss (about
70%) occurs in the LC in PD, and continues throughout
PD (Mavridis et al., 1991; Gesi et al., 2000). Disturbance
of the LC-NE system influences both the onset and progression of neuronal damage in the dopaminergic tract.
A functional LC-NE system benefits the recovery of
damaged dopaminergic neurons (Espay et al., 2014).
Therefore, restoring the damaged central LC-NE
system in PD by augmenting noradrenergic neurotransmission positively impacts the recovery process of degenerated dopaminergic neurons (Paredes-Rodriguez et al.,
2020). However, the strategies targeting the LC-NE
system in PD are currently limited. Although gene therapies for PD have been used in clinical trials (Nakata
et al., 2012; O’Connor and Boulis, 2015), and the lentiviral vector-based gene therapy has been used in patients
with advanced PD at ages 48-65 with promising results
(Palfi et al., 2014). However, whereas none of clinical
applied gene therapy has resulted in significant clinical
benefits, these gene therapies target the genes of the
dopaminergic circuitry that are downregulated in PD.
There is no similar gene therapy aiming at the noradrenergic phenotype. The identification and testing of new
therapeutic genes in this field would be necessary
(Nakata et al., 2012; Bartus et al., 2014; O’Connor and
Boulis, 2015). Therefore, the present study is the first to
use genetic approaches to augment LC-NE function and
further positively impact the recovery process of dopaminergic neurons in PD. It expands our understanding of
molecular mechanisms involved in the facilitating effects
of NE on the DA phenotype expression. It may also provide opportunities for the development of novel therapies
for the treatment of PD.
In summary, the present study demonstrated that
overexpression of transcription factors in the LC of PD
model VMAT2 Lo mice upregulated expression of DBH/
TH in the LC and in the HP and FC, as well as TH
protein levels in the striatum and SN. The enhancement
of noradrenergic and dopaminergic phenotype expression may further increase NE and DA concentrations
in the brain, as measured in the striatum, which was
accompanied by the functional improvement as indicated
by the behavioral performance in a cognitive task and
spontaneous activity. This study carefully investigated
the possibility that symptomatic relief in PD patients as
a result of therapeutic intervention might be related, at
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least in part, to the NE neurotransmitter system. These
results reveal that over-expression of these transcription
factors in the LC can improve noradrenergic and dopaminergic activities and functions in this PD model.
It provides necessary groundwork for the development
of gene therapies of PD, and expands our understanding
of the link between LC-norepinephrine and dopamine
systems during the progression of PD.

Summary Statement
The present study employs forced overexpression of transcription factors in brains to reverse the deficiencies of
noradrenergic neurons in Parkinson’s disease model
mice. The results showed a biochemical and functional
amelioration in degenerating dopamine neurons possibly
through an improved noradrenergic system.
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